Evidence map›Paper›PMID 31213459›Full record

ReviewClinical cancer research : an official journal of the American Association for Cancer Research2019

The Evolving Modern Management of Brain Metastasis.

Peter E Fecci, Cosette D Champion, Jacob Hoj, Courtney M McKernan, C Rory Goodwin, John P Kirkpatrick, Carey K Anders, Ann Marie Pendergast, John H Sampson

Abstract readReview
In one paragraph

Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Whole brain radiotherapy and simultaneous integrated boost: is it still a viable treatment for multiple brain metastases in the era of SRS?Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2026
    Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Peter E FecciDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Cosette D ChampionDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Jacob HojDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina.
Courtney M McKernanDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina.
C Rory GoodwinDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0002-6540-2751
John P KirkpatrickDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Carey K AndersDuke Cancer Institute, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina.
Ann Marie PendergastDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina.
John H SampsonDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina. john.sampson@duke.edu.

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI JOHN N. NORTON · 1985 to 2026
$174.8M
Targeted Alpha-Particle Radiotheraphy of Brain Tumors with 211At-81C6 AntibodyP50CA190991 · NCI · DUKE UNIVERSITY · PI SAMPSON, JOHN H. · 2014 to 2023
$20.8M
Project 3: Phase-2 Trial of Oncolytic Poliovirus (PVSRIPO) combined with CCNU (lomustine) against Recurrent GlioblastomaP01CA225622 · NCI · DUKE UNIVERSITY · PI ASHLEY, DAVID M., GROMEIER, MATTHIAS · 2018 to 2022
$12.2M
Human EGFRvIII-specific BiTE for the treatment of GlioblastomaU01NS090284 · NINDS · DUKE UNIVERSITY · PI SAMPSON, JOHN H. · 2015 to 2019
$5.2M
Brain tumors with regulatory T-cells treated with EGFRvIII-specific T-cellsR01CA177476 · NCI · DUKE UNIVERSITY · PI SAMPSON, JOHN H. · 2013 to 2017
$2.3M
EGFRvIII-targeted Bispecific T cell Engagers for brain tumorsR01NS085412 · NINDS · DUKE UNIVERSITY · PI SAMPSON, JOHN H. · 2013 to 2017
$2.0M
Novel target for therapy refractory lung tumorsR01CA195549 · NCI · DUKE UNIVERSITY · PI PENDERGAST, ANN MARIE · 2015 to 2019
$1.8M
CCL3 as a Developmental Therapeutic to Enhance Brain Tumor TherapyR01NS099463 · NINDS · DUKE UNIVERSITY · PI SAMPSON, JOHN H. · 2017 to 2021
$1.7M
Investigation of an ABL kinase-dependent signaling axis required for lung cancer brain metastasisF31CA224960 · NCI · DUKE UNIVERSITY · PI HOJ, JACOB PETER · 2018 to 2019
$71k
NCI NIH HHS F31 CA224960NCI NIH HHS P01 CA225622NCI NIH HHS P30 CA014236NCI NIH HHS P50 CA190991NCI NIH HHS R01 CA177476NCI NIH HHS R01 CA195549NINDS NIH HHS R01 NS085412NINDS NIH HHS R01 NS099463NINDS NIH HHS U01 NS090284
6 · The paper itself

Abstract

The incidence of brain metastases is increasing as cancer therapies improve and patients live longer, providing new challenges to the multidisciplinary teams that care for these patients. Brain metastatic cancer cells possess unique characteristics that allow them to penetrate the blood-brain barrier, colonize the brain parenchyma, and persist in the intracranial environment. In addition, brain metastases subvert the innate and adaptive immune system, permitting evasion of the antitumor immune response. Better understanding of the above mechanisms will allow for development and delivery of more effective therapies for brain metastases. In this review, we outline the molecular mechanisms underlying development, survival, and immunosuppression of brain metastases. We also discuss current and emerging treatment strategies, including surgery, radiation, disease-specific and mutation-targeted systemic therapy, and immunotherapy.

Indexed as

Blood-Brain BarrierBrain NeoplasmsCellular MicroenvironmentCombined Modality TherapyDisease ManagementDisease SusceptibilityHumansPrognosisTreatment OutcomeTumor Escape

Identifiers

PMID31213459
PMCPMC8258430

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.